 |
|
Clinical Consequences and Transmissibility of Drug-Resistant Tuberculosis in Southern Mexico
Maria de Lourdes García-García, MD, DrSc;
Alfredo Ponce-de-León, MD;
Maria Eugenia Jiménez-Corona, MD;
Aída Jiménez-Corona, MD, MSc;
Manuel Palacios-Martínez, MD;
Susana Balandrano-Campos, BA;
Leticia Ferreyra-Reyes, MD;
Luis Juárez-Sandino, CT;
José Sifuentes-Osornio, MD;
Hiram Olivera-Díaz, MSc;
José Luis Valdespino-Gómez, MD, MPH;
Peter M. Small, MD
Arch Intern Med. 2000;160:630-636.
Background Consequences of drug-resistant tuberculosis (TB) in developing countries using directly observed treatment, short-course (DOTS), are not well defined.
Objective To determine the impact of drug resistance on clinical outcome and transmission of TB under programmatic conditions.
Patients and Methods A prospective cohort and molecular epidemiologic study was conducted in southern Mexico. Between March 1995 and February 1998 all patients with persistent cough whose sputa had acid-fast bacilli (AFB) underwent clinical and mycobacteriologic evaluation (species identification, drug susceptibility testing, and IS6110-based genotyping). Treatment was provided in accordance with Mexico's National Tuberculosis Program. Clinical and microbiologic outcomes and molecular epidemiologically defined transmission were measured.
Results Mycobacterium tuberculosis was isolated from 238 of the 284 AFB smear–positive persons. The overall rate of resistance was 28.4% (new, 20.7%; retreated, 54.7%), and 10.8% (new, 3.3%; retreated, 35.8%) had multi–drug-resistant TB (ie, resistance to isoniazid and rifampin). After treatment, 75% (new, 81.0%; retreated, 52.8%) were cured, 8% (new, 7.8%; retreated, 7.5%) abandoned therapy, 9% (new, 3.9%; retreated, 28.3%) had treatment failure, and 4% (new, 3.3%; retreated, 7.5%) died. Another 2% of patients relapsed, and 9% died during a median of 24.4 months of follow-up. Drug-resistance was a strong independent risk factor for treatment failure. Being infected with multi–drug-resistant TB was the only factor associated with a decreased likelihood of being in a restriction fragment length polymorphism cluster.
Conclusions Despite the use of DOTS, patients with drug-resistant TB had a dramatically increased probability of treatment failure and death. Although multi–drug-resistant TB may have a decreased propensity to spread and cause disease, it has a profoundly negative impact on TB control.
From the Instituto Nacional de Salud Pública, Cuernavaca, Mexico (Drs García-García, M. Jiménez-Corona, A. Jiménez-Corona, Palacios-Martínez, Ferreyra-Reyes, and Valdespino-Gómez and Mr Juárez-Sandino); Stanford University, Stanford, Calif (Dr Small); Instituto Nacional de la Nutrición Salvador Zubirán, (Drs Ponce-de-León and Sifuentes-Osornio), and Instituto Nacional de Diagnóstico y Referencia Epidemiológicos (Ms Balanrano-Campos and Mr Olivera-Díaz), Mexico City, Mexico.
RELATED ARTICLES
Resistance to Antituberculosis Medications: Hard Lessons to Learn
Donald A. Enarson
Arch Intern Med. 2000;160(5):581-582.
EXTRACT
| FULL TEXT
Survey of Drug Resistance of Mycobacterium tuberculosis in 3 Mexican States, 1997
Reuben M. Granich, Susana Balandrano, Adalberto J. Santaella, Nancy J. Binkin, Kenneth G. Castro, Alma Marquez-Fiol, Georgina Anzaldo, Margarita Zarate, Maria Luisa Jaimes, Oscar Velazquez-Monroy, Lourdes Salazar, Carlos Alvarez-Lucas, Pablo Kuri, Ana Flisser, Jose Santos-Preciado, Cuauhtemoc Ruiz-Matus, Roberto Tapia-Conyer, and Jordan W. Tappero
Arch Intern Med. 2000;160(5):639-644.
ABSTRACT
| FULL TEXT
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(5):718-719.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis
Kim et al.
Eur Respir J 2006;28:576-580.
ABSTRACT
| FULL TEXT
Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis.
Hazbon et al.
Antimicrob. Agents Chemother. 2006;50:2640-2649.
ABSTRACT
| FULL TEXT
Gender differentials of pulmonary tuberculosis transmission and reactivation in an endemic area
Jimenez-Corona et al.
Thorax 2006;61:348-353.
ABSTRACT
| FULL TEXT
Role of embB Codon 306 Mutations in Mycobacterium tuberculosis Revisited: a Novel Association with Broad Drug Resistance and IS6110 Clustering Rather than Ethambutol Resistance
Hazbon et al.
Antimicrob. Agents Chemother. 2005;49:3794-3802.
ABSTRACT
| FULL TEXT
Clinical and Radiographic Correlates of Primary and Reactivation Tuberculosis: A Molecular Epidemiology Study
Geng et al.
JAMA 2005;293:2740-2745.
ABSTRACT
| FULL TEXT
Molecular Epidemiology of Tuberculosis
Barnes and Cave
NEJM 2003;349:1149-1156.
FULL TEXT
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis
Am. J. Respir. Crit. Care Med. 2003;167:603-662.
FULL TEXT
Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru
Mitnick et al.
NEJM 2003;348:119-128.
ABSTRACT
| FULL TEXT
Molecular epidemiology of tuberculosis
Burgos and Pym
Eur Respir J 2002;20:54S-65s.
ABSTRACT
| FULL TEXT
Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis
Dye et al.
Science 2002;295:2042-2046.
ABSTRACT
| FULL TEXT
The Burden of Drug-Resistant Tuberculosis and Mechanisms for Its Control
RAVIGLIONE et al.
Ann. N. Y. Acad. Sci. 2001;953:88-97.
ABSTRACT
| FULL TEXT
Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis: Treatment Outcomes in 6 Countries
Espinal et al.
JAMA 2000;283:2537-2545.
ABSTRACT
| FULL TEXT
Resistance to Antituberculosis Medications: Hard Lessons to Learn
Enarson
Arch Intern Med 2000;160:581-582.
FULL TEXT
|
